John Mercer

Dr. John Mercer

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2019 in Advanced Science
Verified
Journal Article
Open access
PDF file
DHDaniel Hoare
Daniel Hoare
ABAnubhav Bussooa
Anubhav Bussooa
SNSteven Neale
Steven Neale
NMNosrat Mirzai
Nosrat Mirzai
JMJohn Mercer
John Mercer
Cardiovascular disease is the greatest cause of death worldwide. Atherosclerosis is the underlying pathology responsible for two thirds of these deaths. It is the age‐dependent process of “furring of the arteries.” In many scenarios the disease is caused by poor diet, high blood pressure, and genetic risk factors, and is exacerbated by obesity, diabetes, and sedentary lifestyle. Current pharmacological anti‐atherosclerotic modalities still fail to control the disease and improvements in clinical interventions are urgently required. Blocked atherosclerotic arteries are routinely treated in hospitals with an expandable metal stent. However, stented vessels are often silently re‐blocked by developing “in‐stent restenosis,” a wound response, in which the vessel's lumen renarrows by excess proliferation of vascular smooth muscle cells, termed hyperplasia. Herein, the current stent technology and the future of biosensing devices to overcome in‐stent restenosis are reviewed. Second, with advances in nanofabrication, new sensing methods and how researchers are investigating ways to integrate biosensors within stents are highlighted. The future of implantable medical devices in the context of the emerging “Internet of Things” and how this will significantly influence future biosensor technology for future generations are also discussed.

1 January 2018 in Atherosclerosis
Verified
Journal Article
Open access
CDCraig Docherty
Craig Docherty
ACAndy Carswell
Andy Carswell
EFElaine Friel
Elaine Friel
JMJohn Mercer
John Mercer
DNA damage and mitochondrial dysfunction are thought to play an essential role in ageing and the energetic decline of vascular smooth muscle cells (VSMCs) essential for maintaining plaque integrity. We aimed to better understand VSMCs and identify potentially useful compensatory pathways that could extend their lifespan. Moreover, we wanted to assess if defects in mitochondrial respiration exist in human atherosclerotic plaques and to identify the appropriate markers that may reflect a switch in VSMC energy metabolism. Human plaque tissue and cells were assessed for composition and evidence of DNA damage, repair capacity and mitochondrial dysfunction. Fresh plaque tissue was evaluated using high resolution oxygen respirometry to assess oxidative metabolism. Recruitment and processing of the mitochondrial regulator of autophagy Pink1 kinase was investigated in combination with transcriptional and protein markers associated with a potential switch to a more glycolytic metabolism. Human VSMC have increased nuclear (nDNA) and mitochondrial (mtDNA) damage and reduced repair capacity. A subset of VSMCs within plaque cap had decreased oxidative phosphorylation and expression of Pink1 kinase. Plaque cells demonstrated increased glycolytic activity in response to loss of mitochondrial function. A potential compensatory glycolytic program may act as energetic switch via AMP kinase (AMPK) and hexokinase 2 (Hex2). We have identified a subset of plaque VSMCs required for plaque stability that have increased mitochondrial dysfunction and decreased oxidative phosphorylation. Pink1 kinase may initiate a cellular response to promote a compensatory glycolytic program associated with upregulation of AMPK and Hex2.

18 April 2023 in IEEE Transactions on Antennas and Propagation
Verified
Journal Article
Open access
JZJungang Zhang
Jungang Zhang
RDRupam Das
Rupam Das
DHDaniel Hoare
Daniel Hoare
HWHuxi Wang
Huxi Wang
AOAfesomeh Ofiare
Afesomeh Ofiare
Hadi HeidariHadi Heidari
Hadi Heidari
Arteriovenous grafts (AVGs) are indispensable life-saving implants for chronic kidney disease (CKD) patients undergoing hemodialysis. However, AVGs will often fail due to postoperative complications such as cellular accumulation termed restenosis, blood clots, and infections, which are dominant causes of morbidity and mortality. A new generation of hemodialysis implants equipped with biosensors and multi-band antennas for wireless power and telemetry systems that can detect specific pathological parameters and report AVGs’ patency would be transformative for CKD. Our study proposes a compact dual-band implantable antenna for hemodialysis monitoring applications. It operates in 1.4 GHz and 2.45 GHz for wireless power transfer and biotelemetry purposes. The miniaturized antenna with a current size of 5 × 5 × 0.635 mm 3 exhibits wide bandwidth (300 MHz at 1.4 GHz band and 380 MHz at 2.45 GHz band), along with good impedance matching at two resonance frequencies. In addition, simulations are performed separately in a three-layer homogenous phantom and a realistic human body model. Measurements of the proposed antenna are evaluated in minced pork. The measured results of the fabricated antenna prototype are closely harmonized with the simulation ones, and the effect of different proportions of fat tissue in pork mince was analyzed, to verify the sensitivity of the antenna to the contacting medium. The specific absorption rate (SAR) and link budget calculation are also analyzed. Finally, the wireless biotelemetry function of the proposed antenna is realized and visualized by adopting a pair of nRF24L01 wireless transceivers, and sustainable and stable wireless data transmission characteristics are shown at a high data rate of 2 Mbps with up to 20 cm transmission distance.

22 June 2018 in Sensors
Verified
Journal Article
Open access
PDF file
ABAnubhav Bussooa
Anubhav Bussooa
SNSteven L Neale
Steven L Neale
JMJohn Mercer
John Mercer
Cardiovascular disease remains the leading cause of death in Western society. Recent technological advances have opened the opportunity of developing new and innovative smart stent devices that have advanced electrical properties that can improve diagnosis and even treatment of previously intractable conditions, such as central line access failure, atherosclerosis and reporting on vascular grafts for renal dialysis. Here we review the latest advances in the field of cardiovascular medical implants, providing a broad overview of the application of their use in the context of cardiovascular disease rather than an in-depth analysis of the current state of the art. We cover their powering, communication and the challenges faced in their fabrication. We focus specifically on those devices required to maintain vascular access such as ones used to treat arterial disease, a major source of heart attacks and strokes. We look forward to advances in these technologies in the future and their implementation to improve the human condition.

14 September 2021 in IEEE Reviews in Biomedical Engineering
Verified
Journal Article
Open access
AMAntonia Molloy
Antonia Molloy
KBKirsten Beaumont
Kirsten Beaumont
AAAli Alyami
Ali Alyami
MKMahmut Kirimi
Mahmut Kirimi
DHDaniel Hoare
Daniel Hoare
JMJohn Mercer
John Mercer
Cardiovascular disease (CVD) is a group of heart and vasculature conditions which are the leading form of mortality worldwide. Blood vessels can become narrowed, restricting blood flow, and drive the majority of hearts attacks and strokes. Reactive surgical interventions are frequently required; including percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Despite successful opening of vessels and restoration of blood flow, often in-stent restenosis (ISR) and graft failure can still occur, resulting in subsequent patient morbidity and mortality. A new generation of cardiovascular implants that have sensors and real-time monitoring capabilities are being developed to combat ISR and graft failure. Self-reporting stent/graft technology could enable precision medicine-based and predictive healthcare by detecting the earliest features of disease, even before symptoms occur. Bringing an implantable medical device with wireless electronic sensing capabilities to market is complex and often obstructive undertaking. This critical review analyses the obstacles that need to be overcome for self-reporting stents/grafts to be developed and provide a precision-medicine based healthcare for cardiovascular patients. Here we assess the latest research and technological advancement in the field, the current devices; including smart cardiovascular implantable biosensors and associated wireless data and power transfer solutions. We include an evaluation of devices that have reached clinical trials and the market potential for their end-user implementation.

26 May 2016 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
CDCraig Docherty
Craig Docherty
ISIan Salt
Ian Salt
JMJohn Mercer
John Mercer
Background: Loss of a cell’s capacity to generate sufficient energy for cellular functions is a key hallmark of the ageing process and ultimately leads to a variety of important age-related pathologies such as cancer, Parkinson’s disease and atherosclerosis. Regenerative medicine has sought to reverse these pathologies by reprogramming somatic cells to a more juvenile energetic state using a variety of stem cell factors. One of these factors, Lin28, is considered a candidate for modification in the reprogramming of cellular energetics to ameliorate the ageing process while retaining cell phenotype.Results: Over-expression of Lin28A resulted in key changes to cellular metabolism not observed in wild-type controls. Extracellular pH flux analysis indicated that Lin28A over expression significantly increased the rate of glycolysis, whilst high resolution oxygen respirometry demonstrated a reduced oxygen consumption. Western blot and real-time PCR analysis identified Hexokinase II as one of the key modulators of glycolysis in these cells which was further confirmed by increased glucose transport. A metabolic switching effect was further emphasised by Western blot analysis where the oxygen consuming mitochondrial complex IV was significantly reduced after Lin28A over expression.Conclusions: Results from this study confirm that Lin28A expression promotes metabolic switching to a phenotype that relies predominantly on glycolysis as an energy source, while compromising oxidative phosphorylation. Mechanisms to augment regulated Lin28A in age related pathologies that are characterised by mitochondria dysfunction or in differentiated and aged post-mitotic cells is the future goal of this work.